



Sheet 1 of 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31220X2C2R2	SERIAL NO. 10/024,858
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Leonard, et al.	
		FILING DATE December 18, 2001	GROUP 1625 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Final Clinical Report 29060/451, 18 March 1996, pp. 1-42.
	Final Clinical Report 29060/474, 17 October 1997, pp. 1-48.
	Final Clinical Report 29060/452, 17 April 1996, pp. I-XVIII, 1-34 and 171-182.
	Rapaport, et al., J. Clin. Psychiatry, 2003, Vol. 64, pp. 1065-1074.
	Golden, et al., J. Clin. Psychiatry, 2002, Vol. 63, pp. 577-584.
	DeVane, J. Clin. Psychiatry, 2003, Vol. 64, Suppl. 18, pp. 14-19.
	Nemeroff, J. Clin. Psychiatry, 2003, Vol. 64, Suppl. 18, p. 25-30.
EXAMINER	DATE CONSIDERED
	03/13/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

n:\wjd\paroxetine\p31220 paxil cr\supp. pto 1449 jan 2006.doc